4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Trends in Antimicrobial Resistance Patterns in Neisseria Gonorrhoeae in Australia and New Zealand: A Meta-analysis and Systematic Review

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          (1) Background: The widespread development of resistance among Neisseria gonorrhoeae (NG) clinical isolates has been reported by surveillance systems around the world. This meta-analysis estimated the changes in susceptibility patterns among antibiotics under surveillance in Australia and New Zealand. (2) Methods: Articles published in English from 1980–2018, from Australia or New Zealand, that met the selection criteria were included. The meta-analysis was carried out using the R statistical software. (3) Results: In Australia, there has been decreasing susceptibility of gonococcal isolates to selected antimicrobials over time. Azithromycin (Odds Ratio (OR): 0.73; 95% Confidence Interval (CI) 0.64–0.82) and ceftriaxone (OR: 0.69; 95% CI 0.59–0.80) showed decreasing levels of susceptibility each year. Western Australia (OR: 0.76; 95% CI 0.60–0.96) and Victoria (OR: 0.74; 95% CI 0.60–0.90) also had decreasing levels of susceptibility to ceftriaxone over time compared with other states and territories. (4) Conclusions: The results highlight the need for the development of new approaches for managing cases of gonorrhoea. Improved antimicrobial stewardship, enhanced surveillance and contact tracing are needed to identify and respond to changes in antibiotic resistance in a timely manner. Increasing awareness and public health follow-up of cases can help to interrupt the cycle of infection and limit transmission.

          Related collections

          Most cited references67

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action

          In a Policy Forum, Teodora Wi and colleagues discuss the challenges of antimicrobial resistance in gonococci.
            Bookmark
            • Record: found
            • Abstract: not found
            • Book: not found

            Meta: An R Package for Meta-Analysis.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge

              Neisseria gonorrhoeae has developed antimicrobial resistance (AMR) to all drugs previously and currently recommended for empirical monotherapy of gonorrhoea. In vitro resistance, including high-level, to the last option ceftriaxone and sporadic failures to treat pharyngeal gonorrhoea with ceftriaxone have emerged. In response, empirical dual antimicrobial therapy (ceftriaxone 250–1000 mg plus azithromycin 1–2 g) has been introduced in several particularly high-income regions or countries. These treatment regimens appear currently effective and should be considered in all settings where local quality assured AMR data do not support other therapeutic options. However, the dual antimicrobial regimens, implemented in limited geographic regions, will not entirely prevent resistance emergence and, unfortunately, most likely it is only a matter of when, and not if, treatment failures with also these dual antimicrobial regimens will emerge. Accordingly, novel affordable antimicrobials for monotherapy or at least inclusion in new dual treatment regimens, which might need to be considered for all newly developed antimicrobials, are essential. Several of the recently developed antimicrobials deserve increased attention for potential future treatment of gonorrhoea. In vitro activity studies examining collections of geographically, temporally and genetically diverse gonococcal isolates, including multidrug-resistant strains particularly with resistance to ceftriaxone and azithromycin, are important. Furthermore, understanding of effects and biological fitness of current and emerging (in vitro induced/selected and in vivo emerged) genetic resistance mechanisms for these antimicrobials, prediction of resistance emergence, time-kill curve analysis to evaluate antibacterial activity, appropriate mice experiments, and correlates between genetic and phenotypic laboratory parameters, and clinical treatment outcomes, would also be valuable. Subsequently, appropriately designed, randomized controlled clinical trials evaluating efficacy, ideal dose, toxicity, adverse effects, cost, and pharmacokinetic/pharmacodynamics data for anogenital and, importantly, also pharyngeal gonorrhoea, i.e. because treatment failures initially emerge at this anatomical site. Finally, in the future treatment at first health care visit will ideally be individually-tailored, i.e. by novel rapid phenotypic AMR tests and/or genetic point of care AMR tests, including detection of gonococci, which will improve the management and public health control of gonorrhoea and AMR. Nevertheless, now is certainly the right time to readdress the challenges of developing a gonococcal vaccine.
                Bookmark

                Author and article information

                Journal
                Antibiotics (Basel)
                Antibiotics (Basel)
                antibiotics
                Antibiotics
                MDPI
                2079-6382
                23 October 2019
                December 2019
                : 8
                : 4
                : 191
                Affiliations
                [1 ]Public Health Unit, South Western Sydney Local Health District, Liverpool, NSW 2170, Australia; Mithilesh.Dronavalli@ 123456health.nsw.gov.au (M.D.); Kate.Alexander3@ 123456health.nsw.gov.au (K.A.); Sayontonee.Ghosh@ 123456health.nsw.gov.au (S.G.); Leng.Boonwaat@ 123456health.nsw.gov.au (L.B.); Zeel.Patel@ 123456health.nsw.gov.au (Z.P.); Naru.Pal@ 123456health.nsw.gov.au (N.P.)
                [2 ]Public Health Unit, Nepean Blue Mountains Local Health District, Penrith, NSW 2750, Australia; Jane.Thomas@ 123456health.nsw.gov.au (J.T.); Amanda.Robinson2@ 123456health.nsw.gov.au (A.R.); Bradley.Forssman@ 123456health.nsw.gov.au (B.F.)
                Author notes
                [* ]Correspondence: Stephanie.Fletcher@ 123456health.nsw.gov.au ; Tel.: +61-2-8778-0855
                Author information
                https://orcid.org/0000-0002-8897-2351
                https://orcid.org/0000-0003-2870-9030
                Article
                antibiotics-08-00191
                10.3390/antibiotics8040191
                6963718
                31652729
                6a532d84-f8f9-4715-8e5f-e1026d8fbcab
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 19 August 2019
                : 22 October 2019
                Categories
                Article

                neisseria gonorrhoeae,sexually transmitted infections,surveillance,antibiotic resistance,antimicrobial testing,australia,new zealand

                Comments

                Comment on this article